Introducing Galleri®

Screen for more cancers with a single blood test1

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

Waist up portrait of Black woman with curly brown hair wearing purple scrubs and a stethoscope smiling at the camera

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

Finally, multi-cancer early detection is possible with only a blood draw

purple text indicating 1 in 3

More than 1 out of 3 individuals will develop cancer in their lifetime.2

purple text indicating approximately 70%

~70% of cancer deaths are from cancers without recommended screening options3

purple text indicating 5/100

Only 5 out of >100 known cancer types have recommended screening tests4

How the Galleri test works

The Galleri test scans a blood sample for a cancer-specific signal found on cell-free DNA (cfDNA). If detected, Galleri localizes the origin of the cancer signal with high accuracy.5

Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. Galleri should be used in addition to healthcare provider recommended screening tests

illustrated mechanism of action video indicating a cancer signal detected over top a strand of pink DNA

50+ cancer types

The Galleri test detects a signal shared by 50+ cancer types. In clinical studies, the following cancers were diagnosed after a Cancer Signal Detected result with the Galleri test.1

A

  • Adrenal Cortical Carcinoma
  • Ampulla of Vater
  • Anus
  • Appendix, Carcinoma

B

  • Bile Ducts, Distal
  • Bile Ducts, Intrahepatic
  • Bile Ducts, Perihilar
  • Bladder, Urinary
  • Bone
  • Breast

C

  • Cervix
  • Colon and Rectum

E

  • Esophagus and Esophagogastric Junction

G

  • Gallbladder
  • Gastrointestinal Stromal Tumor
  • Gestational Trophoblastic Neoplasms

K

  • Kidney

L

  • Larynx
  • Leukemia
  • Liver
  • Lung
  • Lymphoma (Hodgkin and Non-Hodgkin)

M

  • Melanoma of the Skin
  • Merkel Cell Carcinoma
  • Mesothelioma, Malignant Pleural

N

  • Nasal Cavity and Paranasal Sinuses Nasopharynx
  • Neuroendocrine Tumors of the Appendix
  • Neuroendocrine Tumors of the Colon and Rectum
  • Neuroendocrine Tumors of the Pancreas

O

  • Oral Cavity
  • Oropharynx (HPV-Mediated, p16+)
  • Oropharynx (p16-) and Hypopharynx
  • Ovary, Fallopian Tube and Primary Peritoneum

P

  • Pancreas, exocrine
  • Penis
  • Plasma Cell Myeloma and Plasma Cell Disorders
  • Prostate

S

  • Small Intestine
  • Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs
  • Soft Tissue Sarcoma of the Head and Neck
  • Soft Tissue Sarcoma of the Retroperitoneum
  • Soft Tissue Sarcoma of the Trunk and Extremities
  • Soft Tissue Sarcoma Unusual Histologies and Sites
  • Stomach

T

  • Testis

U

  • Ureter, Renal Pelvis
  • Uterus, Carcinoma and Carcinosarcoma
  • Uterus, Sarcoma

V

  • Vagina
  • Vulva

Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.

Supported by robust clinical data, Galleri sets the standard for multi-cancer early detection

20,000+ individuals participated in large clinical studies1,5
Text reading: "GRAIL collaborated with leading cancer institutes to study the Galleri test" followed by logos for the Cleveland Clinic, Dana-Farber Cancer Institute, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Intermountain Healthcare, Icahn School of Medicine at Mount Sinai, Sutter Health, UHN Princess Margaret Cancer Centre, Benoroya Research Institute Virginia Mason, Sarah Cannon, Hartford HealthCare Cancer Institute, The US Oncology Network, Knight Cancer Institute, The Christ Hospital Lindner Research Center

Ordering Galleri for your patients is easy

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Order the test

The Galleri test can be ordered through the Provider Portal or by completing a paper Test Requisition Form.

illustrated graphic of a white, gray haired female patient having her blood drawn

Patient specimen collection

Galleri uses a single blood draw. For more information, refer to our Specimen Collection Instructions.

External phlebotomy providers are available nationwide.

Illustrated graphic of a tan female doctor with brown hair and blue glasses reviewing the results of a Galleri test

Receive test results

Galleri test results are available about 2 weeks after a patient’s sample has been received at GRAIL’s laboratory. 

Ordering providers receive an email notification when test results are ready. Results can be accessed via the Provider Portal.

Get Started

Complete this form and a GRAIL representative will reach out to you. 

Not a healthcare provider? There are other options for contacting us here.

  1. What describes you best?

  2. What are you looking for?

  3. Fill in the form

    We care about your privacy. Our Privacy Policy

    Please login to the Provider Portal if you are already an ordering provider.

    We care about your privacy. Our Privacy Policy

    We care about your privacy. Our Privacy Policy

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of ​“No Cancer Signal Detected” does not rule out cancer. A test result of ​“Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI: https://doi.org/10.1016/j.annonc.2021.05.806.

  2. American Cancer Society. Lifetime Risk of Developing or Dying From Cancer. https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/lifetime-probability-of-developing-or-dying-from-cancer.html.

  3. American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022 https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html. Data on file GA-2021-0065.

  4. US Preventive Services Task Force. A,B,C Grade Recommendations Cancer. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results.

  5. Schrag D, McDonnall CH, Naduld L, et al. PATHFINDER: A Prospective Study of a Multi-Cancer Early Detection Blood Test. Presentation at European Society of Medical Oncology (ESMO) Congress September 9-13, 2022; Paris, France. https://grail.com/wp-content/uploads/2022/09/Schrag_903O_ESMO-2022_Pathfinder-Main_Proferred-Paper-Oral-Presentation.pdf.